CIK 0001540171 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Avalyn Pharma Inc.
Sign in to watch- Ticker
- AVLN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 452463191
- Phone
- (206) 707-0340
- Business address
- 105 W FIRST ST., BOSTON, MA, 02127
- Former names
- Genoa Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,701,004
- in 1 filing
Net −$6,701,004. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | FMR LLC 10% owner | Conversion · Series C-2 Preferred Stock | −225,843 | 0 | ||
| 2026-05-01 | FMR LLC 10% owner | Conversion · Series D Preferred Stock | −377,948 | 0 | ||
| 2026-05-01 | Carroll Jill Director | Conversion | +1,419,298 | 1,419,298 | ||
| 2026-05-01 | Carroll Jill Director | Conversion | +489,486 | 1,908,784 | ||
| 2026-05-01 | Carroll Jill Director | Purchase | +277,778 | $18.00 | $5.0M | 2,186,562 |
| 2026-05-01 | Carroll Jill Director | Conversion · Series C-1 Convertible Preferred Stock | −27,309,719 | 0 | ||
| 2026-05-01 | Carroll Jill Director | Conversion · Series D Convertible Preferred Stock | −9,418,561 | 0 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +1,419,298 | 1,419,298 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +489,486 | 1,908,784 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Purchase | +277,778 | $18.00 | $5.0M | 2,186,562 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +354,824 | 354,824 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +489,486 | 844,310 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Purchase | +277,777 | $18.00 | $5.0M | 1,122,087 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series C-1 Convertible Preferred Stock | −27,309,719 | 0 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series D Convertible Preferred Stock | −9,418,561 | 0 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series C-1 Convertible Preferred Stock | −6,827,429 | 0 | ||
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series D Convertible Preferred Stock | −9,418,560 | 0 | ||
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion | +1,275,486 | 1,275,486 | ||
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion · Series C-1 Convertible Preferred Stock | −20,482,289 | 0 | ||
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion · Series D Convertible Preferred Stock | −4,060,259 | 0 |
Page 2 of 3 · 49 trades